Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BGM Group Ltd. stock logo
BGM
BGM Group
$9.57
+0.2%		$8.45
$6.45
▼
$303.00
$121.34M1.856,927 shs13,180 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.31
-0.3%		$1.30
$0.85
▼
$2.23
$33.57M1.79525,389 shs620 shs
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$2.57
-1.0%		$3.25
$1.62
▼
$5.05
$110.42M2.071.04 million shs28,264 shs
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
$32.08
+6.7%		$33.21
$8.94
▼
$73.00
$112.68M1.2910,788 shs3,675 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BGM Group Ltd. stock logo
BGM
BGM Group
-5.12%+1.70%+25.03%+9.02%-96.68%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-0.76%-9.03%+24.76%-25.99%-2.96%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-4.07%-10.69%-25.79%-38.92%-15.08%
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
-23.61%-19.11%+2.88%+171.21%+180.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BGM Group Ltd. stock logo
BGM
BGM Group
$9.57
+0.2%		$8.45
$6.45
▼
$303.00
$121.34M1.856,927 shs13,180 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.31
-0.3%		$1.30
$0.85
▼
$2.23
$33.57M1.79525,389 shs620 shs
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$2.57
-1.0%		$3.25
$1.62
▼
$5.05
$110.42M2.071.04 million shs28,264 shs
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
$32.08
+6.7%		$33.21
$8.94
▼
$73.00
$112.68M1.2910,788 shs3,675 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BGM Group Ltd. stock logo
BGM
BGM Group
-5.12%+1.70%+25.03%+9.02%-96.68%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-0.76%-9.03%+24.76%-25.99%-2.96%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-4.07%-10.69%-25.79%-38.92%-15.08%
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
-23.61%-19.11%+2.88%+171.21%+180.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BGM Group Ltd. stock logo
BGM
BGM Group
1.00
SellN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.00
Buy$6.00359.42% Upside
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
2.43
Hold$34.501,245.03% Upside
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest NNVC, RFAI, BGM, and NRXP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D+) ➝ Hold (C-)
9/14/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$10.00
9/4/2026
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D) ➝ Sell (D+)
8/26/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
8/26/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
8/25/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
8/21/2026
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold (C-) ➝ Sell (D)
8/18/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$10.00
8/10/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
8/7/2026
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D+) ➝ Hold (C-)
8/7/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$10.00
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BGM Group Ltd. stock logo
BGM
BGM Group
$47.90M2.53N/AN/A$121.05 per share0.08
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$1.23M90.30N/AN/A($0.54) per share-4.75
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BGM Group Ltd. stock logo
BGM
BGM Group
-$19.94MN/AN/AN/AN/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.40N/AN/AN/AN/A-87.90%-78.69%N/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$28.62M-$0.55N/AN/AN/A-691.81%N/A-63.92%11/13/2026 (Estimated)
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest NNVC, RFAI, BGM, and NRXP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/28/2026Q2 2026
BGM Group Ltd. stock logo
BGM
BGM Group
N/A-$0.30N/A-$0.0050N/A$12.15 million
8/14/2026Q2 2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$0.1067-$0.44-$0.3333-$0.44$1.33 million$1.10 million
8/7/2026Q2 2026
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/A$0.01N/A$0.01N/AN/A
7/21/2026Q4 2025
BGM Group Ltd. stock logo
BGM
BGM Group
N/A-$80.70N/A-$2.6850N/A$11.80 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BGM Group Ltd. stock logo
BGM
BGM Group
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/AN/A
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BGM Group Ltd. stock logo
BGM
BGM Group
N/A
1.25
0.73
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/A
0.86
0.86
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
BGM Group Ltd. stock logo
BGM
BGM Group
N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
4.27%
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/A

Insider Ownership

CompanyInsider Ownership
BGM Group Ltd. stock logo
BGM
BGM Group
58.66%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
3.60%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
6.40%
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
39.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
BGM Group Ltd. stock logo
BGM
BGM Group
47112.69 million5.25 millionN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
725.53 million14.92 millionOptionable
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
2943.30 million40.53 millionOptionable
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
23.51 million2.14 millionN/A

Recent News About These Companies

RF Acquisition Corp II (NASDAQ:RFAI) Stock Moved Up to Sell by Wall Street Zen
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104243
Aktien»Nachrichten»STABLECOINX AKTIE»Morning Market Movers: RF Acquisition Corp II, SU Group, T3 Defense, StablecoinX See Big Swings
October 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69375394-morning-market-movers-rf-acquisition-corp-ii-su-group-t3-defense-stablecoinx-see-big-swings-020.htm
RF Acquisition Corp II (NASDAQ:RFAI) Short Interest Update
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-rf-acquisition-corp-ii-nasdaq-rfai-short-interest-update-2026-10-01/
Cours RF Acquisition Corp II
September 26, 2026  |  zonebourse.comZ
The9 Reports US$32 Million Net Income for Second Quarter of 2026, Up Over 39% Sequentially
August 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/the9-reports-us32-million-net-income-for-second-quarter-of-2026-up-over-39-sequentially-302858240.html
RF Acquisition Corp II Ordinary Shares
August 21, 2026  |  livemint.comhttps://www.livemint.com/market/market-stats/us-stocks-rf-acquisition-corp-ii-share-price-rfai
RF Acquisition Corp. Stock Skyrockets Following Key SEC Filings
August 21, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/08/61353509/rf-acquisition-corp-stock-skyrockets-following-key-sec-filings
RF Acquisition Corp II Shareholders Approve Merger Plans
August 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rf-acquisition-corp-ii-shareholders-approve-merger-plans?utm_source=marketbeat.com&utm_medium=referral
RF Acquisition Corp II Shareholders Approve Extension Amendments
August 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rf-acquisition-corp-ii-shareholders-approve-extension-amendments?utm_source=marketbeat.com&utm_medium=referral
RF Acquisition Corp II (RFAI) Holds Steady Near Support as SPAC Trading Remains Tepid - Day Trade Opportunities
July 14, 2026  |  donanimhaber.comD
HCC Healthcare Signs Business Combination Agreement with RF Acquisition Corp III to Go Public on Nasdaq
July 9, 2026  |  quiverquant.comQ
Rf Acquisition Corp II
June 29, 2026  |  fool.comhttps://www.fool.com/quote/nasdaq/rfai/
RF Acquisition Corp. II Rt
April 15, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/rfair
RF Acquisition Corp. II
April 8, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/rfai
RF Acquisition Corp III Completes Initial Public Offering of 10 Million Units on Nasdaq
February 18, 2026  |  quiverquant.comQ
RF Acquisition Corp III Prices Initial Public Offering of 10 Million Units at $10.00 Each on Nasdaq
February 12, 2026  |  quiverquant.comQ
RF Acquisition Corp II Announces Merger with Nanyang Biologics
October 2, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rf-acquisition-corp-ii-announces-merger-with-nanyang-biologics?utm_source=marketbeat.com&utm_medium=referral
RF Acquisition Corp II Audit Committee Resignation
May 21, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rf-acquisition-corp-ii-audit-committee-resignation?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM Group stock logo

BGM Group NASDAQ:BGM

$9.56 +0.02 (+0.16%)
As of 09:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.31 0.00 (-0.31%)
As of 09:45 AM Eastern
This is a fair market value price provided by Massive. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

NRx Pharmaceuticals stock logo

NRx Pharmaceuticals NASDAQ:NRXP

$2.56 -0.03 (-0.97%)
As of 09:45 AM Eastern
This is a fair market value price provided by Massive. Learn more.

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

RF Acquisition Corp II stock logo

RF Acquisition Corp II NASDAQ:RFAI

$32.08 +2.03 (+6.74%)
As of 09:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

RF Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 5, 2024, and is headquartered in Singapore.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas